Intellia Therapeutics Inc Stock News

Gene-editing stocks have gotten pummeled by the market's growing aversion to risk. Nonetheless, the field has made substantial progress of late.

Intellia has declined over the past year even as its candidates for severe diseases have advanced in clinical studies. The company aims to launch a phase 3 trial for one of its candidates as early as

Intellia's leading candidates look promising, but there's a long way to go before they hit the market. If the company can deliver regular clinical and regulatory wins, its stock could provide outsized

Intellia Therapeutics has a pair of promising gene-editing therapies in the works. It also has a highly technically advanced program that could enter trials soon.

Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases,

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD

Rocket Pharmaceuticals has two programs approaching commercialization. By contrast, Intellia's candidates won't be ready for quite some time.

Cathie Wood likes to buy innovative and disruptive companies. She's been buying both Intellia Therapeutics and Ginkgo Bioworks recently.

Cathie Wood has been buying shares of Intellia since December -- but she recently increased the pace of those transactions. Intellia could become a leader in the innovative field of gene editing.

Cathie Wood bought shares of Palantir, Intellia Therapeutics, and Accolade on Thursday. Palantir was downgraded by a prominent analyst on Thursday, and it recently posted its weakest quarterly revenue

Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority vote

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Editas Medicine encountered problems with one of its top candidates last year, while the other still has a long way to go. Intellia Therapeutics has a solid financial position, a partner with big pock

Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $1.33 per share a year ago.